| Katherine Gordon, CCC SLP | |
|
320 N Loretto Rd, Lebanon, KY 40033-1300 | |
| (270) 699-5788 | |
| Not Available |
| Full Name | Katherine Gordon |
|---|---|
| Gender | Female |
| Speciality | Speech-language Pathologist |
| Location | 320 N Loretto Rd, Lebanon, Kentucky |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1710346887 | NPI | - | NPPES |
| 0640 | Other | KY | KY LICENSE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 235Z00000X | Speech-language Pathologist | (* (Not Available)) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Katherine Gordon, CCC SLP 320 N Loretto Rd, Lebanon, KY 40033-1300 Ph: (270) 699-5788 | Katherine Gordon, CCC SLP 320 N Loretto Rd, Lebanon, KY 40033-1300 Ph: (270) 699-5788 |
News Archive
Chronic pain is a condition that affects one in five Americans without regard for their race or finances. But a new study finds that minorities and people with low incomes have less access than high-income white people to the medications that will help them endure their pain.
A team of researchers from the University of California San Diego and Mexico has found that even a modest behavioral intervention program averaging just 35 minutes can measurably reduce the incidence of HIV and sexually transmitted infections among female sex workers in the U.S.-Mexico border region - and that the program succeeds at comparatively little expense.
Researchers at the La Jolla Institute for Allergy & Immunology have added a significant milestone to scientific understanding of the role viruses play in the development of autoimmune diseases, such as diabetes.
In 2010, after allegations of fraud among some fund recipients in several countries, the Global Fund to Fight AIDS, Tuberculosis and Malaria convened "an independent, high-level panel to review its financial controls and how grant money is spent," and the Fund "is now implementing the panel's recommendations," PlusNews reports.
ARIAD Pharmaceuticals, Inc., today announced top-line data showing that ridaforolimus, an investigational oral mTOR inhibitor, met the primary endpoint of improved progression-free survival (PFS) compared to placebo in the Phase 3 SUCCEED trial conducted in patients with metastatic soft-tissue or bone sarcomas who previously had a favorable response to chemotherapy.
› Verified 3 days ago
Mrs. Elizabeth Tapp Raley, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 108 Palm St, Lebanon, KY 40033 Phone: 859-481-4734 | |
Communication Beyond Limits, Plc Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 71 Meadow Ln, Lebanon, KY 40033 Phone: 270-402-3923 | |
Robert Lee, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 71 Meadow Ln, Lebanon, KY 40033 Phone: 270-402-3923 | |
Sarah Smith, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 533 Indian Creek Rd, Lebanon, KY 40033 Phone: 859-481-1492 | |
Amber Clark, MS, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 60 W Calvary Dr, Lebanon, KY 40033 Phone: 270-779-4143 | |
Mrs. Lori Jo Milby, SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 193 Westside Dr, Lebanon, KY 40033 Phone: 270-692-5655 |